Vertex Pharmaceuticals Inc
XETRA:VX1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
V
|
Vertex Pharmaceuticals Inc
XETRA:VX1
|
US |
|
Sociedad Quimica y Minera de Chile SA
NYSE:SQM
|
CL |
|
NCS Multistage Holdings Inc
F:MUH0
|
US |
|
J
|
JCDecaux SA
F:DCS
|
FR |
|
C
|
Compagnie Generale des Etablissements Michelin SCA
XBER:MCH
|
FR |
|
S
|
Sinclair Broadcast Group Inc
F:SBTA
|
US |
|
M
|
MPHB Capital Bhd
KLSE:MPHBCAP
|
MY |
|
B
|
Barco NV
F:BC1P
|
BE |
|
B
|
Bumi Resources Minerals Tbk PT
SWB:BUR
|
ID |
|
M
|
Magnis Energy Technologies Ltd
F:U1P
|
AU |
|
Rapt Therapeutics Inc
NASDAQ:RAPT
|
US |
|
R
|
Restaurant Brands International Inc
LSE:0VFA
|
CA |
|
M
|
McDonald's Corp
XBER:MDO
|
US |
|
Electro Optic Systems Holdings Ltd
ASX:EOS
|
AU |
|
Deutsche EuroShop AG
OTC:DUSCF
|
DE |
Wall St Price Targets
VX1 Price Targets Summary
Vertex Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for VX1 is 477.81 EUR with a low forecast of 285.02 EUR and a high forecast of 575.55 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is VX1's stock price target?
Price Target
477.81
EUR
According to Wall Street analysts, the average 1-year price target for VX1 is 477.81 EUR with a low forecast of 285.02 EUR and a high forecast of 575.55 EUR.
What is the Revenue forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
10%
Over the last 13 years, the compound annual growth rate for Revenue has been 17%. The projected CAGR for the next 8 years is 10%.
What is the Operating Income forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
15%
Over the last 13 years, the compound annual growth rate for Operating Income has been 42%. The projected CAGR for the next 8 years is 15%.
What is the Net Income forecast for Vertex Pharmaceuticals Inc?
Projected CAGR
15%
The compound annual growth rate for Net Income over the next 8 years is 15%.
